Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

Neuro-Oncology

Volumn 17, Issue 9, 2015, Pages 1188-1198

  Ellingson, Benjamin M ^a,q,r,s,v,w   Bendszus, Martin ^b,t   Boxerman, Jerrold ^c,s,w,x   Barboriak, Daniel ^d,s,v,w   Erickson, Bradley J ^e,u,v,w   Smits, Marion ^f,t   Nelson, Sarah J ^g,r   Gerstner, Elizabeth ^h,q,u   Alexander, Brian ⁱ   Goldmacher, Gregory ^j,v   Wick, Wolfgang ^b,t   Vogelbaum, Michael ^k,y   Weller, Michael ^l   Galanis, Evanthia ^e   Kalpathy Cramer, Jayashree ^h   Shankar, Lalitha ^m   Jacobs, Paula ^m   Pope, Whitney B ^a,q,w   Yang, Dewen ^j   Chung, Caroline ⁿ   Knopp, Michael V ^o,v   Cha, Soonme ^g   Van Den Bent, Martin J ^f,t   Chang, Susan ^g   Al Yung, W K ^p   Cloughesy, Timothy F ^a   Wen, Patrick Y ⁱ   Gilbert, Mark R ^m,y   Whitney, Andrew ^z   Sandak, David ^aa   Musella, Al ^ab   Haynes, Chas ^ac   Wallace, Max ^aa   Arons, David F ^ad   Kingston, Ann ^ad   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c BROWN UNIVERSITY   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MAYO CLINIC   (United States)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

^j ICON Medical Imaging   (United States)

^k LERNER RESEARCH INSTITUTE   (United States)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ PRINCESS MARGARET HOSPITAL   (Canada)

^o THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^p UNIVERSITY OF TEXAS   (United States)

^q Adult Brain Tumor Consortium (ABTC)   (United States)

^r Ivy Consortium for Early Phase Clinical Trials   (United States)

^s American College of Radiology Imaging Network (ACRIN)   (United States)

^t European Organisation for Research and Treatment of Cancer (EORTC)   (United States)

^u Alliance for Clinical Trials in Oncology   (United States)

^v RSNA Quantitative Imaging Biomarker Alliance (QIBA)   (United States)

^w American Society of Neuroradiology   (United States)

^x American Society of Functional Neuroradiology (ASFNR)   (United States)

^y Radiation Therapy Oncology Group (RTOG)   (United States)

^z Morgan Lewis LLP   (United States)

^aa Accelerate Brain Cancer Cure   (United States)

^ab Musella Foundation   (United States)

^ac Musella Foundation ^*  (United States)

^ad Brain Tumor Society   (United States)

more..

Author keywords

Brain Tumor Imaging Protocol; clinical trials; glioblastoma; MRI

Indexed keywords

BEVACIZUMAB; NITROSOUREA; TEMOZOLOMIDE; CONTRAST MEDIUM;

ALZHEIMER DISEASE; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); CONSENSUS DEVELOPMENT; CONTRAST ENHANCEMENT; CONTRAST TO NOISE RATIO; DIFFUSION WEIGHTED IMAGING; DRUG DEVELOPMENT; FOOD AND DRUG ADMINISTRATION; GLIOBLASTOMA; HUMAN; MULTICENTER STUDY (TOPIC); NATIONAL HEALTH ORGANIZATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; SIGNAL NOISE RATIO; STANDARDIZATION; THREE DIMENSIONAL IMAGING; TREATMENT OUTCOME; TREATMENT RESPONSE; IMAGE ENHANCEMENT; PATHOLOGY; PROCEDURES; STANDARDS;

BRAIN NEOPLASMS; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; CONTRAST MEDIA; HUMANS; IMAGE ENHANCEMENT; MAGNETIC RESONANCE IMAGING; NEUROIMAGING;

EID: 84940726872     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov095     Document Type: Review

References (62)

1. Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014;16(Suppl 4): iv1-i63.
2. Weller M, van den Bent M, Hopkins K, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol. 2014;15(9):e395-e403.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
4. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013;31(32):4085-4091.
5. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
6. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
7. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
8. Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma-are we there yet? Neuro Oncol. 2013;15(1):4-27.
9. Ellingson BM, Wen PY, van den Bent MJ, et al. Prosand cons of current brain tumor imaging. Neuro Oncol. 2014;16:(Suppl 7):vii2-vi11.
10. Wen PY, Cloughesy TF, Ellingson BM, et al. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014;16(Suppl 7):vii36-vii47.
11. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008;10(2):162-170.
12. Macdonald DR, Cascino TL, Schold SC Jr., et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
13. Provenzale JM, Ison C, Delong D. Bidimensional measurements in brain tumors: assessment of interobserver variability. AJR Am J Roentgenol. 2009;193(6):W515-W522.
14. Ellingson BM, Bendszus M, Sorensen AG, et al. Emerging techniques and technologies in brain tumor imaging. Neuro Oncol. 2014;16(Suppl 7):vii12-vii23.
15. Reardon DA, Ballman KV, Buckner JC, et al. Impact of imaging measurements on response assessment in glioblastoma clinical trials. Neuro Oncol. 2014;16(Suppl 7):vii24-vii35.
16. Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1100-1108.
17. Akeson P, Vikhoff B, Stahlberg F, et al. Brain lesion contrast in MR imaging. Dependence on field strength and concentration of gadodiamide injection in patients and phantoms. Acta Radiol. 1997;38(1):14-18.
18. Nobauer-Huhmann IM, Ba-Ssalamah A, Mlynarik V, et al. Magnetic resonance imaging contrast enhancement of brain tumors at 3 tesla versus 1.5 tesla. Invest Radiol. 2002;37(3):114-119.
19. Mueller SG, Weiner MW, Thal LJ, et al. Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement. 2005;1(1): 55-66.
20. Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am. 2005;15(4): 869-877, xi-xii.
21. Jack CR Jr., Bernstein MA, Borowski BJ, et al. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement. 2010;6(3):212-220.
22. Leow AD, Klunder AD, Jack CR Jr., et al. Longitudinal stability of MRI for mapping brain change using tensor-based morphometry. Neuroimage. 2006;31(2):627-640.
23. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer. 1996; 77:362-372.
24. Wesseling P, van der Laak JA, Link M, et al. Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy. Hum Pathol. 1998;29(4):352-358.
25. Vos MJ, Uitdehaag BM, Barkhof F, et al. Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology. 2003;60(5):826-830.
26. Dempsey MF, Condon BR, Hadley DM. Measurement of tumor "size" in recurrent malignant glioma: 1D, 2D, or 3D? AJNR Am J Neuroradiol. 2005;26(4):770-776.
27. Chow KL, Gobin YP, Cloughesy T, et al. Prognostic factors in recurrent glioblastoma multiforme and anaplastic astrocytoma treated with selective intra-arterial chemotherapy. AJNR Am J Neuroradiol. 2000;21(3):471-478.
28. Reeves GI, Marks JE. Prognostic significance of lesion size for glioblastoma multiforme. Radiology. 1979;132(2):469-471.
29. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol. 1988; 6(2):338-343.
30. Warren KE, Patronas N, Aikin AA, et al. Comparison of one-, two-, and three-dimensional measurements of childhood brain tumors. J Natl Cancer Inst. 2001;93(18):1401-1405.
31. Galanis E, Buckner JC, Maurer MJ, et al. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro Oncol. 2006; 8(2):156-165.
32. Gallego Perez-Larraya J, Lahutte M, Petrirena G, et al. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST+ F criteria. Neuro Oncol. 2012;14(5):667-673.
33. Hopper KD, Kasales CJ, Van Slyke MA, et al. Analysis of interobserver and intraobserver variability in CT tumor measurements. AJR Am J Roentgenol. 1996;167(4):851-854.
34. Lavin PT, Flowerdew G. Studies in variation associated with the measurement of solid tumors. Cancer. 1980;46(5):1286-1290.
35. Quoix E, Wolkove N, Hanley J, et al. Problems in radiographic estimation of response to chemotherapy and radiotherapy in small cell lung cancer. Cancer. 1988;62(3):489-493.
36. Thiesse P, Ollivier L, Di Stefano-Louineau D, et al. Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Francais d'Immunotherapie of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol. 1997;15(12): 3507-3514.
37. Warr D, McKinney S, Tannock I. Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol. 1984;2(9):1040-1046.
38. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11): 1963-1972.
39. Reuter M, Gerstner ER, Rapalino O, et al. Impact of MRI head placement on glioma response assessment. J Neurooncol. 2014; 118(1):123-129.
40. Brant-Zawadzki M, Gillan GD, Nitz WR. MP RAGE: a three-dimensional, T1-weighted, gradient-echo sequence-initial experience in the brain. Radiology. 1992;182(3):769-775.
41. Brant-Zawadzki MN, Gillan GD, Atkinson DJ, et al. Three-dimensional MR imaging and display of intracranial disease: improvements with the MP-RAGE sequence and gadolinium. J Magn Reson Imaging. 1993;3(4):656-662.
42. Fellner F, Holl K, Held P, et al. AT1-weighted rapid three-dimensional gradient-echo technique (MP-RAGE) in preoperative MRI of intracranial tumours. Neuroradiology. 1996;38(3):199-206.
43. Runge VM, Kirsch JE, Thomas GS, et al. Clinical comparison of three-dimensional MP-RAGE and FLASH techniques for MR imaging of the head. J Magn Reson Imaging. 1991;1(4):493-500.
44. van den Hauwe L, Parizel PM, Van Goethem JW, et al. Clinical usefulness of contrast-enhanced MP-RAGE of the brain. Neuroradiology. 1996;38(Suppl 1):S14-S19.
45. Downs RK, Bashir MH, Ng CK, et al. Quantitative contrast ratio comparison between T1 (TSE at 1.5 T, FLAIR at 3 T), magnetization prepared rapid gradient echo and subtraction imaging at 1.5 T and 3 T. Quant Imaging Med Surg. 2013;3(3):141-146.
46. Nagao E, Yoshiura T, Hiwatashi A, et al. 3D turbo spin-echo sequence with motion-sensitized driven-equilibrium preparation for detection of brain metastases on 3 T MR imaging. AJNR Am J Neuroradiol. 2011;32(4):664-670.
47. Suto Y, Caner BE, Tamagawa Y, et al. Subtracted synthetic images in Gd-DTPA enhancedMR. J Comput Assist Tomogr. 1989;13(5):925-928.
48. Lloyd GA, Barker PG, Phelps PD. Subtraction gadolinium enhanced magnetic resonance for head and neck imaging. Br J Radiol. 1993; 66(781):12-16.
49. Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in amulticenter clinical trial. Radiology. 2014;271(1):200-210.
50. Damadian R. Tumor detection by nuclear magnetic resonance. Science. 1971;171(3976):1151-1153.
51. Weisman ID, Bennett LH, Maxwell LR Sr., et al. Recognition of cancer in vivo by nuclear magnetic resonance. Science. 1972; 178(4067):1288-1290.
52. Hollis DP, Economou JS, Parks LC, et al. Nuclear magnetic resonance studies of several experimental and human malignant tumors. Cancer Res. 1973;33(9):2156-2160.
53. Hazlewood CF, Cleveland G, Medina D. Relationship between hydration and proton nuclear magnetic resonance relaxation times in tissues of tumor-bearing and non-tumor-bearing mice: implications for cancer detection. J Natl Cancer Inst. 1974;52(6): 1849-1853.
54. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-787.
55. Pai A, Li X, Majumdar S. A comparative study at 3 T of sequence dependence of T2 quantitation in the knee. Magn Reson Imaging. 2008;26(9):1215-1220.
56. Wintersperger BJ, Runge VM, Biswas J, et al. Brain tumor enhancement in MR imaging at 3 Tesla: comparison of SNR and CNR gain using TSE and GRE techniques. Invest Radiol. 2007; 42(8):558-563.
57. Akeson P, Nordstrom CH, Holtas S. Time-dependency in brain lesion enhancement with gadodiamide injection. Acta Radiol. 1997;38(1):19-24.
58. Ellingson BM, Malkin MG, Rand SD, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging. 2010;31(3): 538-548.
59. Sugahara T, Korogi Y, Kochi M, et al. Usefulness of diffusionweighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999;9(1): 53-60.
60. Chenevert TL, Stegman LD, Taylor JM, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92(24): 2029-2036.
61. Guo AC, Cummings TJ, Dash RC, et al. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology. 2002;224(1):177-183.
62. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11(2):102-125.